Zacks Investment Research upgraded shares of Asterias Biotherapeutics Inc (NYSE:AST) from a hold rating to a buy rating in a research report released on Wednesday morning. The firm currently has $2.75 target price on the biotechnology company’s stock.
According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “
Separately, HC Wainwright reiterated a buy rating and issued a $12.00 target price on shares of Asterias Biotherapeutics in a research report on Monday, October 2nd.
Shares of Asterias Biotherapeutics (NYSE:AST) traded up 2.04% during trading on Wednesday, hitting $2.50. The stock had a trading volume of 96,464 shares. Asterias Biotherapeutics has a 12 month low of $2.45 and a 12 month high of $5.80. The company’s market cap is $124.95 million. The stock has a 50 day moving average of $3.16 and a 200 day moving average of $3.30.
Asterias Biotherapeutics (NYSE:AST) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.25 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. Equities analysts forecast that Asterias Biotherapeutics will post ($0.61) EPS for the current fiscal year.
WARNING: “Asterias Biotherapeutics Inc (AST) Upgraded to “Buy” by Zacks Investment Research” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/26/asterias-biotherapeutics-inc-ast-upgraded-to-buy-by-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently modified their holdings of AST. Teachers Advisors LLC increased its stake in Asterias Biotherapeutics by 13.1% during the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 6,714 shares during the last quarter. State Street Corp increased its stake in Asterias Biotherapeutics by 24.1% during the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after acquiring an additional 63,773 shares during the last quarter. California State Teachers Retirement System increased its stake in Asterias Biotherapeutics by 4.6% during the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,100 shares during the last quarter. Finally, Family Management Corp increased its stake in Asterias Biotherapeutics by 15.6% during the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 6,416 shares during the last quarter.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.